Atlas Trials

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Clinical trial NCT06462092 · RECRUITING

Trial details

NCT number
NCT06462092
Sponsor
Guangzhou Medical University
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Leptomeningeal Metastases
Start date
2026-01-01
Primary completion
2027-01-15
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.